ONCO
Onconetix, Inc.NASDAQHealthcare$1.53+0.66%ClosedMarket Cap: $5.2M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.32
P/S
6.43
EV/EBITDA
-0.00
DCF Value
$1.40
FCF Yield
-184.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.6%
Operating Margin
-2190.0%
Net Margin
-1721.0%
ROE
-189.8%
ROA
-56.3%
ROIC
-112.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $303.6K | 81.6% | $-1.3M | $5.7M | $1.04 | — |
| FY 2025 | $815.4K | 77.6% | $-6.3M | $-14.0M | $-4.73 | — |
| Q3 2025 | $303.7K | 88.6% | $-2.1M | $-8.8M | $-1.79 | — |
| Q2 2025 | $106.5K | 66.2% | $-1.9M | $-2.4M | $-1.36 | — |
| Q1 2025 | $101.6K | 45.1% | $-12.6M | $-8.5M | $-514.86 | — |
| Q4 2024 | $712.0K | 92.7% | $-29.1M | $-29.4M | $-4.97 | — |
| FY 2024 | $2.5M | 41.8% | $-56.5M | $-58.7M | $-520.93 | — |
| Q3 2024 | $406.9K | 25.9% | $-2.6M | $-3.8M | $-0.84 | — |
| Q2 2024 | $704.8K | 14.3% | $-13.6M | $-14.3M | $-0.18 | — |
| Q1 2024 | $700.4K | 27.0% | $-11.1M | $-11.1M | $-0.14 | — |
| Q4 2023 | $58.5K | -1941.8% | $-5.4M | $-22.4M | $-0.29 | — |
| FY 2023 | $58.5K | -1927.9% | $-36.0M | $-37.4M | $-25.03 | — |